News for BiomX Inc. (PHGE-UN)

BiomX (PHGE) has initiated its Phase 2b trial for the BX004 phage therapy, targeting antibiotic-resistant Pseudomonas aeruginosa infections in cystic fibro

BiomX (PHGE) has initiated patient dosing in its Phase 2b clinical trial, marking a significant step in developing BX004, a treatment aimed at cystic fibrosis p

First patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results are expected in Q1

Premier research journal article provides validation for BiomX's phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infectionsNew, updated data demonstrates

Shares of Beyond Air, Inc. XAIR fell sharply in today's pre-market trading after the company posted mixed fourth-quarter results. Beyond Air reported quarterly...

BiomX (PHGE) CEO Jonathan Solomon to present at Biomed Israel 2025 Conference on May 21, 2025. Focus on positive topline Phase 2 results for BX211, a ph

**media[630522]**

Analyst Joseph Pantginis from H.C. Wainwright has adjusted the price target for BiomX (PHGE), reducing it from $21 to $15. The adjustment follows the company's

Cash Balance and Restricted Cash: $21.2 million as of March 30, 2025, compared to $18 million as of December 31, 2024.Research and Development Expenses: $5.3 m

May 15, 2025 / 06:00PM GMTOperator Greetings and welcome to the BiomX Inc first quarter 2025 financial results conference call. At this time, all participants a

BiomX Inc. (NYSE:PHGE) Q1 2025 Earnings Conference Call May 15, 2025 2:00 PM ETCompany ParticipantsMarina Wolfson - CFOJonathan Solomon - CEOConference Call...

BiomX (PHGE) reports positive Phase 2 trial results for BX211 in treating diabetic foot osteomyelitis, with statistically significant improvements in ulcer

**media[626768]**

BiomX Inc. (PHGE), a clinical-stage company focused on phage therapies that target specific pathogenic bacteria, announced Monday positive, topline safety and efficacy results from its Phase 2 trial evaluating BX211 for diabetic foot osteomyelitis or DFO.

**media[581154]**

Net Loss: $17.7 million for 2024, a significant improvement from the $26.2 million loss in the previous year.Cash Position: Ended 2024 with $18.0 million in ca

**media[575685]**

**media[571268]**

BiomX Inc. (NYSE:PHGE) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsMarina Wolfson – Chief Financial OfficerJonathan...